Literature DB >> 27823879

New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.

Simon J A van Kuijk1, Nanda Kumar Parvathaneni2, Raymon Niemans3, Marike W van Gisbergen3, Fabrizio Carta4, Daniela Vullo5, Silvia Pastorekova6, Ala Yaromina3, Claudiu T Supuran4, Ludwig J Dubois3, Jean-Yves Winum7, Philippe Lambin3.   

Abstract

Carbonic anhydrase IX (CAIX) is a hypoxia-regulated and tumor-specific protein that maintains the pH balance of cells. Targeting CAIX might be a valuable approach for specific delivery of cytotoxic drugs, thereby reducing normal tissue side-effects. A series of dual-target compounds were designed and synthesized incorporating a sulfonamide, sulfamide, or sulfamate moiety combined with several different anti-cancer drugs, including the chemotherapeutic agents chlorambucil, tirapazamine, and temozolomide, two Ataxia Telangiectasia and Rad3-related protein inhibitors (ATRi), and the anti-diabetic biguanide agent phenformin. An ATRi derivative (12) was the only compound to show a preferred efficacy in CAIX overexpressing cells versus cells without CAIX expression when combined with radiation. Its efficacy might however not solely depend on binding to CAIX, since all described compounds generally display low activity as carbonic anhydrase inhibitors. The hypothesis that dual-target compounds specifically target CAIX expressing tumor cells was therefore not confirmed. Even though dual-target compounds remain an interesting approach, alternative options should also be investigated as novel treatment strategies.
Copyright © 2016 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  CAIX inhibitors; Carbonic anhydrase IX; Cytotoxic drugs; Dual-target drugs; Hypoxia; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27823879     DOI: 10.1016/j.ejmech.2016.10.037

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.

Authors:  Sang-Yong Lee; Vigneshwaran Namasivayam; Nader M Boshta; Arianna Perotti; Salahuddin Mirza; Silvia Bua; Claudiu T Supuran; Christa E Müller
Journal:  RSC Med Chem       Date:  2021-06-16

2.  Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells.

Authors:  Ludwig J Dubois; Daumantas Matulis; Justina Kazokaitė; Raymon Niemans; Virginija Dudutienė; Holger M Becker; Jānis Leitāns; Asta Zubrienė; Lina Baranauskienė; Gabor Gondi; Reinhard Zeidler; Jurgita Matulienė; Kaspars Tārs; Ala Yaromina; Philippe Lambin
Journal:  Oncotarget       Date:  2018-06-01

3.  Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.

Authors:  Emilie Anduran; Ashok Aspatwar; Nanda-Kumar Parvathaneni; Dennis Suylen; Silvia Bua; Alessio Nocentini; Seppo Parkkila; Claudiu T Supuran; Ludwig Dubois; Philippe Lambin; Jean-Yves Winum
Journal:  Molecules       Date:  2020-05-18       Impact factor: 4.411

Review 4.  Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.

Authors:  Claudiu T Supuran
Journal:  J Exp Pharmacol       Date:  2020-12-15

5.  Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies.

Authors:  Chandra Bhushan Mishra; Raj Kumar Mongre; Amresh Prakash; Raok Jeon; Claudiu T Supuran; Myeong-Sok Lee
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

6.  Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization.

Authors:  Huihua Lan; Jianghui Zeng; Gang Chen; Huayi Huang
Journal:  Oncotarget       Date:  2017-11-28

7.  Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment.

Authors:  Mitra Dolatkhah; Yadollah Omidi
Journal:  Bioimpacts       Date:  2019-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.